Nexalin Technology (NXL) Change in Account Payables (2021 - 2026)
Nexalin Technology (NXL) recorded quarterly Change in Account Payables of -$76480.0 in Q1 2026, down 142.49% quarter-over-quarter from $179996.0 in Q4 2025, and down 400.57% on a YoY basis from $25445.0 in Q1 2025.
Nexalin Technology (NXL) Change in Account Payables (2021 - 2026) Analysis & Trends
Nexalin Technology's Change in Account Payables history runs 6 years deep, the most recent figure standing at -$76480.0 for Q1 2026.
- In Q1 2026, Change in Account Payables fell 400.57% year-over-year to -$76480.0; the TTM figure through Mar 2026 stood at -$13296.0 (down 144.49% YoY), while the FY2025 annual figure was $88629.0, up 2572.22% from the prior year.
- Change in Account Payables was -$76480.0 for Q1 2026 at Nexalin Technology, down from $179996.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $179996.0 in Q4 2025 to a low of -$353609.0 in Q1 2023.
- Historically, Change in Account Payables has averaged -$16257.4 across 5 years, with a median of $3743.0 in 2023.
- The sharpest annual moves came in 2024 and 2025: Change in Account Payables plunged 1819.8% in 2024, then surged 1799.2% in 2025.
- A 5-year view of Change in Account Payables shows it stood at -$139926.0 in 2022, then surged by 162.17% to $86985.0 in 2023, then slumped by 112.18% to -$10593.0 in 2024, then soared by 1799.2% to $179996.0 in 2025, then plunged by 142.49% to -$76480.0 in 2026.
- The last three Change in Account Payables figures came in at -$76480.0 (Q1 2026), $179996.0 (Q4 2025), and -$168228.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | - |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | -198.00 Mn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 221.00 Mn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 56.90 Mn |
| 10 | Nexalin Technology | 7.82 Mn | 5.11 Mn | 13,133.00 | -76,480.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -76,480.00 |
| Mar 31, 2026 | -76,480.00 |
| Dec 31, 2025 | 179,996.00 |
| Dec 31, 2025 | 179,996.00 |
| Sep 30, 2025 | -168,228.00 |
| Sep 30, 2025 | -168,228.00 |
| Jun 30, 2025 | 51,416.00 |
| Jun 30, 2025 | 51,416.00 |
| Mar 31, 2025 | 25,445.00 |
| Mar 31, 2025 | 25,445.00 |
| Dec 31, 2024 | -10,593.00 |
| Dec 31, 2024 | -10,593.00 |
| Sep 30, 2024 | 79,404.00 |
| Sep 30, 2024 | 79,404.00 |
| Jun 30, 2024 | -64,372.00 |
| Jun 30, 2024 | -64,372.00 |
| Mar 31, 2024 | -8,024.00 |
| Mar 31, 2024 | -8,024.00 |
| Dec 31, 2023 | 86,985.00 |
| Dec 31, 2023 | 86,985.00 |